title: Anti-HIV agent MAP30 modulates the expression profile of viral and cellular genes for proliferation and apoptosis in AIDS-related lymphoma cells infected with Kaposi's sarcoma-associated virus.
abstract: The anti-HIV agent MAP30 (Momordica anti-HIV protein, 30 kDa) inhibits the proliferation of BC-2, an AIDS-related primary effusion lymphoma (PEL) cell line derived from an AIDS patient. BC-2 cells are latently infected with Kaposi's sarcoma-associated herpes virus (KSHV), also known as human herpes virus 8 (HHV8). We examined the effect of MAP30 on the expression of viral and cellular genes in BC-2 during latent and lytic states of the viral life cycle. By Northern analysis and RT-PCR, we found that MAP30 downregulates the expression of viral cyclin D (vCD), viral interleukin-6 (vIL-6), and viral FLIP (vFLIP), genes involved in cell cycle regulation, viral pathogenesis, and apoptosis. By pathway-specific cDNA microarray analysis, we found that BC-2 cells express high levels of egr-1, ATF-2, hsp27, hsp90, IkappaB, mdm2, skp1, and IL-2, cellular genes involved in mitogenesis, tumorigenesis, and inhibition of apoptosis in NFkappaB and p53 signaling pathways. These results define for the first time the specific cellular pathways involved in AIDS-related tumorigenesis and suggest specific novel targets for the treatment. Furthermore, we found that MAP30 downregulates the expression of egr-1, ATF-2, hsp27, hsp90, IkappaB, mdm2, and Skp1, while it upregulates the pro-apoptotic-related genes Bax, CRADD, and caspase-3. Thus, MAP30 modulates the expression of both viral and cellular genes involved in KS pathogenesis. These results provide valuable insight into the molecular mechanisms of MAP30 anti-KS action and suggest its utility as a therapeutic agent against AIDS-related tumors.
authors.affiliation: Department of Biochemistry, New York University School of Medicine, New York, NY 10016, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Sun
authors.forename: P L
authors.initials: PL
authors.lastname: Huang
authors.forename: J J
authors.initials: JJ
authors.lastname: Li
authors.forename: Y Q
authors.initials: YQ
authors.lastname: Huang
authors.forename: L
authors.initials: L
authors.lastname: Zhang
authors.forename: P L
authors.initials: PL
authors.lastname: Huang
authors.forename: S
authors.initials: S
authors.lastname: Lee-Huang
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology; D017209:Apoptosis / Q000502:physiology; D020169:Caspases / Q000235:genetics / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects / Q000235:genetics*; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D019288:Herpesvirus 8, Human / Q000235:genetics* / Q000502:physiology; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000473:pathology / Q000821:virology*; D020411:Oligonucleotide Array Sequence Analysis; D010940:Plant Proteins / Q000494:pharmacology*; D054790:Ribosome Inactivating Proteins, Type 2; D012514:Sarcoma, Kaposi / Q000235:genetics; D015398:Signal Transduction / Q000235:genetics; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014764:Viral Proteins / Q000235:genetics / Q000378:metabolism
chemical_list: D019380:Anti-HIV Agents; C066347:MAP30 protein, Momordica charantia; D010940:Plant Proteins; D054790:Ribosome Inactivating Proteins, Type 2; D014764:Viral Proteins; D020169:Caspases; D013755:Tetradecanoylphorbol Acetate